ClinicalTrials.gg
RecruitingNCT06392997GynRNAUpdated Jan 23, 2025

Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology

An observational study in Gynecologic Disease, Gynecologic Cancer and Endometriosis, sponsored by ZIWIG. Recruiting at 13 sites in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by ZIWIG · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Genital Diseases, Female with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Genital Diseases, Female · France.

Started
2024
with 1 other
Observational
2 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
ZIWIG

Among the 10 studies in Genital Diseases, Female with a site in France, this one is one of 2 that started in 2024, is one of 2 observational ones, and was the 8th registered.

Genital Diseases, Female

161 studies on the registry are indexed under Genital Diseases, Female; 31 are open to participants now.

Browse Genital Diseases, Female studies →

Open to participants now

2 of the 10 studies in Genital Diseases, Female with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 21 Genital Diseases, Female studies recruiting now, 10 (48%) set no upper age limit and 11 (52%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Genital Diseases, Female with a site in France, or all of them as a file.
02

Study summary

GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva.

The study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian/cervical/uterine cancer) and asymptomatic females.

The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations necessary according to the context, which are carried out according to the local recommendations.

03

Conditions studied

  • Gynecologic Disease
  • Gynecologic Cancer
  • Endometriosis
  • Ovarian Cancer
  • Cyst Ovary
  • Fibroid
  • Cervical Cancer
  • Uterine Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study populations is constituted of s:

  1. Clinically symptomatic females with one or more of the following gynecological pathology:

    • Endometriosis,
    • Adenomyosis,
    • Ovarian cysts,
    • Fibroids,
    • Ovarian cancer,
    • Cervical cancer
    • Uterine cancer.
  2. Asymptomatic females with:

    • cervical dysplasia or cancer
    • a normal pap-smear (control)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject of legal age (according to local legislation) and at least 18 years old
  2. Subject (and if applicable her legal representative) having dated and signed the form
  3. Subject with a medical insurance policy
  4. Subject presenting to the department:

    1. With Symptoms (bleeding and/or pain and/or clinically observed symptom) of one or more of the following pathologies (suspected undergoing diagnostic surgery/ or diagnosed and before any curative treatment of the pathology):

      • Endometriosis
      • Adenomyosis,
      • Ovarian cysts,
      • Fibroids,
      • Ovarian cancer,
      • Cervical cancer,
      • Uterine cancer.
    2. Asymptomatic with pap smear positive for cervical dysplasia or cervical cancer and before any curative treatment.
    3. Asymptomatic undergoing a pap smear for cervical cancer screening in a gynecological follow-up context.

Exclusion criteria

Exclusion Criteria:

  1. Recent (\<1 month) or ongoing bacterial or viral infection
  2. Known active oral or digestive mycosis
  3. Evolving oral pathology, symptomatic or obvious
  4. Known pregnancy
  5. Known current non-gynecological pelvic pathology
  6. Subject with a diagnosed breast cancer or cancer other than gynecological with the exception of basal cell carcinoma
  7. Subject with a history of treated cancer within the last 5 years with the exception of basal cell carcinoma
  8. Subject who has already received chemotherapy or radiotherapy or undergone complete or partial excision of the gynecological pathology of inclusion criterion
  9. Subject with significant difficulties reading or writing her language
  10. Subject unable to comply with study and/or follow-up procedures
  11. Participation in an interventional study with drug or in the exclusion period of an interventional study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Symptomatic group

    Clinically symptomatic females with one or more of the following gynecological pathology: * Endometriosis, * Adenomyosis, * Ovarian cysts, * Fibroids, * Ovarian cancer, * Cervical cancer * Uterine cancer.

    Diagnostic Test: Saliva sample

  • Asymptomatic group

    Asymptomatic females with: * Cervical dysplasia or cancer * A normal pap-smear (control)

    Diagnostic Test: Saliva sample

Interventions

  • Diagnostic testSaliva sample

    Saliva sample

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of the Receiver Operating Curve (ROC)

    Identify a diagnostic signature for each pathology (Endometriosis / Adenomyosis / Ovarian cysts / Fibroids / Cervical Displasia / Ovarian cancer / Cervical cancer /Uterine cancer) by analyzing of coding and non-coding RNA contained in the saliva.

    Time frame: Through the end of study inclusions, an average of 1 year

07

Study locations

5 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
May 1, 2024
StartActual
Dec 5, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06392997
Lead sponsor
ZIWIG
Collaborators
Monitoring Force Group
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Dec 5, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 23, 2025

Study contacts

Sofiane Bendifallah, MD
Contact
sofiane.bendifallah@yahoo.fr
+33146412699

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion